MRC1 and colorectal cancer: Interestingly, González et al. also found a higher percentage (26%) of MMR-d in stage II SBAs compared with stage III (18%) or stage IV (0%) SBAs.13 In addition, fewer MMR-d/MSI-high cancers were found among stage IV colorectal cancers.27 This behavior might be explained in part by the more prominent anti-tumor immune response which is frequent and well documented in MMR-d cancers.